Neutralizing response elicited by homologous and heterologous prime booster vaccination against ancestral SARS-CoV-2 B.1, P.1, C.37 and B.1.617.2 variants

Blanco, Sebastián ORCID: https://orcid.org/0000-0001-7832-2833, Spinsanti, Lorena ORCID: https://orcid.org/0000-0002-0157-4570, Aguilar, Juan Javier, Diaz, Adrián, Beranek, Mauricio, Fernández, Elmer Andrés, Mangeaud, Arnaldo Pedro ORCID: https://orcid.org/0000-0002-7370-7256, Konigheim, Brenda Salomé ORCID: https://orcid.org/0000-0003-1724-2156 and Gallego, Sandra Verónica (2022) Neutralizing response elicited by homologous and heterologous prime booster vaccination against ancestral SARS-CoV-2 B.1, P.1, C.37 and B.1.617.2 variants. Vaccine, 40 (47). pp. 6706-6710. ISSN 0264-410X

PDF - Otro Disponible bajo Licencia CC Atribución-NoComercial-SinDerivadas 4.0 Internacional. Descargar (70kB)

Resumen

Heterologous Covid-19 vaccination strategies arose due to interruption of vaccination programs plus delay and shortage of vaccine supplies. We analysed neutralizing response against ancestral SARS-CoV-2 B.1 and P.1, C.37 and B.1.67.2 variants elicited by 16 homologous and heterologous protocols combining Gam-COVID-Vac, ChAdOx1-S, Ad5-nCorV, BBIBP-CorV and mRNA-1273 vaccines. Homologous mRNA-1273 and heterologous schemes of a non-replicative viral vector/inactivated virus-based vaccine combined with mRNA-1273 induced significantly broader and greater neutralizing antibody-response. Moreover, serum from participants vaccinated with combinations of ChAdOx1-S/Ad5-nCorV and BBIBP-CorV/non-replicative viral vector-based vaccines showed higher or equivalent neutralizing response compared to homologous protocols, pointing them as good alternative platforms. BBIBP-CorV used as second dose exhibited significantly lower neutralizing response compared to other protocols, demonstrating that it should not be recommended as second dose. The information provided herein is valuable to redesign vaccination strategies, especially for low-income countries that still struggle with low percentages of immunized populations and vaccine supply shortage.

Tipo de documento:	Artículo
DOI:	https://doi.org/10.1016/j.vaccine.2022.10.021
Palabras clave:	COVID-19. Vacunación heteróloga. Anticuerpos neutralizantes. Variantes.
Temas:	R Medicina > R Medicina (General) R Medicina > RB Patología
Unidad académica:	Universidad Católica de Córdoba > Unidad Asociada a CONICET
Google Académico:	Ver citaciones
URI:	http://pa.bibdigital.ucc.edu.ar/id/eprint/3507

Editar ítem